Monitoring for Skull and Brain Metastases: Understanding Scan Reports

When you are living with cancer, a new phrase in a scan report—such as "increased tracer uptake," "enhancing lesion," "sclerotic focus," or "abnormal marrow signal"—can immediately raise the biggest fear: Is this active cancer or progression?

The honest answer is that no single scan always settles that question on its own. Different scans look at different parts of the problem: bone structure, bone repair activity, tumour metabolism, marrow, soft tissue, the brain, and the lining around the brain. A report becomes much more useful when the radiologist and oncology team compare it with earlier studies, symptoms, treatment timing, and other scan types.

This page explains what the common tests can and cannot show, why scan findings sometimes seem to conflict, and how to ask for clear follow-up.

First: skull bone versus brain metastases

These are related but different locations, and the most useful scan may differ.

Skull or calvarial metastasis means cancer involving the bone of the skull.

Brain metastasis means cancer involving brain tissue itself.

Dural involvement means disease affecting the protective lining around the brain.

A lesion can involve skull bone without involving the brain.

A brain MRI may assess the brain, the dura, and much of the skull marrow. CT is especially helpful for the mineralised structure of the skull bone. PET and bone scans add information about metabolic activity or bone turnover.

What each scan is showing

A useful way to remember it

Bone scan: "Is the bone remodelling here?"

CT: "What does the bone physically look like?"

PET: "Is this area taking up tracer/metabolically active?"

MRI: "What is happening in the marrow, soft tissue, dura and brain?"

Each test can contribute a piece. No scan is a perfect, stand-alone test for "active cancer."

What does "increased uptake" mean?

The phrase means different things depending on the scan.

On a bone scan

"Increased tracer uptake" means the tracer has collected more strongly in an area where the bone is turning over or repairing itself. It can occur with a bone metastasis, but it can also occur with healing bone, prior radiation, injury, a fracture, inflammation, or benign bone conditions.

A bone scan hotspot should therefore be interpreted with the report's overall impression and compared with CT, MRI, PET, earlier bone scans, symptoms and treatment history.

On an FDG-PET scan

"Increased uptake" usually means a tissue is taking up more glucose tracer. Many cancers do this, but activated inflammatory and healing tissues can do it too. The SUV is a semi-quantitative number, not a direct count of live cancer cells.

On MRI

MRI does not usually use the phrase "uptake." Instead, reports may describe abnormal marrow signal, enhancement, restricted diffusion, oedema, or soft-tissue/dural involvement.

Why one scan may show something another does not

It can be unsettling when a bone scan shows a new area of uptake but the CT performed the same day does not mention it—or when a PET performed earlier did not show it. This does not automatically mean that one scan is wrong.

Different tests detect different biology and may become abnormal at different stages.

The most productive next step is not to decide based on a single phrase, but to ask whether the finding has been correlated across the available scans and whether a defined follow-up plan is needed.

Can a scan prove "active cancer"?

Usually, imaging can provide evidence that is more or less concerning, but it may not be able to prove biological activity from one isolated scan.

Features that may raise concern include:

• A new lesion in a pattern typical of metastatic disease

• Increase in size or number of lesions over time

• New or increasing soft-tissue component

• New cortical destruction or progressive lytic change on CT

• Progressive marrow replacement or extension toward the dura/brain on MRI

• Increasing PET uptake in a lesion that also enlarges or changes structurally

• Worsening symptoms that fit the affected site

Features that can be reassuring, while still requiring clinical interpretation, include:

• No new lesions and stable appearance on serial imaging

• Shrinking soft-tissue component or less extensive abnormal marrow on MRI

• Stable or improving symptoms

• Bone sclerosis/remineralisation after treatment, when the overall pattern supports healing

• A transient post-treatment bone-scan increase that settles or stabilises on follow-up

Why serial comparison matters

A scan is a snapshot. A planned series of scans can show whether an area is changing in a concerning, stable or treatment-response direction.

For a known skull lesion or a new skull hotspot, it is important to learn:

Is this finding new, or was it present in retrospect on earlier imaging?

Which earlier scans were directly compared?

Has the area grown, shrunk or remained stable?

Is there a change in MRI marrow signal or enhancement?

Is there any soft-tissue, scalp, dural, venous-sinus or brain involvement?

Can the existing CT or PET/CT be reviewed in bone windows for the skull focus?

Does the pattern fit active/progressive disease, treated/healing change, or an indeterminate finding needing follow-up?

Which scan is best for the next comparison, and when should it be repeated?

Try to compare like with like where possible: brain MRI with a prior brain MRI, CT bone windows with a prior CT, PET with a prior PET, and bone scan with a prior bone scan. Cross-comparison is still valuable, but a direct same-modality comparison is often the clearest way to see true change.

MRI with and without contrast

For suspected or known skull, dural or brain involvement, MRI with and without gadolinium contrast is often valuable because the two parts provide complementary information.

Without contrast

Non-contrast MRI shows baseline anatomy and can identify abnormal replacement of normal fatty marrow in the skull. It also assesses the brain for oedema, bleeding, fluid-related change and diffusion abnormalities.

With contrast

Gadolinium contrast helps abnormal tissue stand out by highlighting areas with altered blood supply or leaky vessels. It can improve visibility of small lesions and clarify lesion margins. It is especially useful to assess:

Enhancement within a skull lesion

Adjacent scalp or soft-tissue component

Dural enhancement or involvement

Extension toward a venous sinus or the brain

Small brain metastases

However, contrast does not selectively identify cancer cells. Tumour can enhance, but inflammation, healing and radiation-related changes can enhance too. That is why the radiologist interprets the complete MRI pattern and compares it with earlier studies.

CT bone windows: a useful question

"Bone windows" are specialised CT viewing settings that make subtle bone detail easier to see. They may be available from a CT already performed; sometimes the existing images simply need a targeted review or reconstruction rather than a whole new scan.

For a skull focus, CT bone windows may help show:

Lytic or "punched-out" bone loss

Sclerosis or dense bone formation

Mixed lytic/sclerotic change

Cortical erosion or involvement of the inner or outer skull table

Expansion, fracture or structural repair

A helpful question is:

"Could the existing CT or PET/CT images be reviewed in bone windows for the skull area seen on my bone scan? If the skull is not adequately shown, would a targeted thin-slice CT with bone reconstructions help?"

Prepare for the next scan

Patients are not responsible for interpreting their own images, but they can help ensure the radiology team has the right clinical question and comparison information.

Before or at the scan:

Tell the imaging staff about the known skull lesion or prior hotspot.

Ask whether the relevant prior scans are available in the same imaging system.

Use the intake form or speak to staff to note the location clearly, for example: "Prior bone scan: increased uptake/right frontal skull focus—please compare if possible."

Bring or arrange transfer of outside reports/images if studies were done at another facility.

Tell the team about new focal pain, tenderness, a palpable bump, headache, visual symptoms, numbness, weakness or other neurological changes.

After the scan:

Ask for the report and keep a dated copy.

Confirm whether the report explicitly compared the prior hotspot/lesion.

Ask what the planned next comparison is and what would prompt earlier assessment.

Questions to take to oncology or radiology

You can copy and adapt these:

"My scan mentions increased uptake/abnormality in the skull. What exactly is this scan measuring: bone turnover, metabolism, bone structure, marrow, or enhancement?"

"Was this area visible on my earlier scans, including in retrospect? Which scans were directly compared?"

"Is there a structural correlate on CT bone windows or a marrow/soft-tissue correlate on MRI?"

"Does the pattern look more consistent with progression, treated/healing change, radiation effect, or something indeterminate?"

"Is there any extension into scalp tissue, dura, venous sinuses or brain?"

"What is the specific monitoring plan: which scan, what interval, and what change would alter treatment?"

"Can the report explicitly comment on the prior skull finding so it is tracked at the next scan?"

Group member experience shared

Why this is a helpful advocacy step: The person is not deciding what the hotspot means. They are making sure the clinical team knows it exists, has the relevant prior images, and explicitly compares it on follow-up. That can reduce the risk that an important finding is lost among different scan types or different imaging facilities.

Bottom line

A new area of uptake or an abnormality in the skull deserves careful attention, but it is not the same as a definitive verdict of progression. Bone scan, CT, PET and MRI see different features of disease and healing. The clearest answer often comes from a combination of:

The exact scan finding and its location

Direct comparison with prior imaging

The right complementary scan when needed

Symptoms and examination

Treatment and radiation timing

A written, specific follow-up plan

Being informed and asking for comparison is not being difficult. It is a practical way to participate in good monitoring while your oncology and radiology teams make the medical interpretation.

References

1. Garfinkle J, Melançon D, Cortes M, Tampieri D. Imaging pattern of calvarial lesions in adults. 2011. Skeletal Radiology. 40(10):1261–1273.
   Especially useful for: the complementary roles of CT and MRI; CT for bony lesions and MRI—particularly with paramagnetic contrast—for marrow and extra-osseous involvement.
   PubMedpubmed.ncbi.nlm.nih

2. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. 2015. World Journal of Radiology. 7(8):202–211.
   Especially useful for: explaining the biology and strengths/limitations of CT, MRI, bone scan, PET/CT, and hybrid imaging in skeletal metastasis.
   PubMedpubmed.ncbi.nlm.nih

3. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. 2005. Seminars in Nuclear Medicine. 35(2):135–142.
   Especially useful for: the distinction between tumour-directed/metabolic imaging and bone-remodelling tracers.
   PubMed

4. Oprea-Lager DE, et al. Molecular Imaging of Bone Metastases and Their Response to Therapy. 2020. Journal of Nuclear Medicine. 61(6):799–806.
   Especially useful for: why conventional imaging and bone scintigraphy can be nonspecific for early response assessment, and the role of SPECT/CT, PET/CT, PET/MRI, and whole-body diffusion-weighted MRI.
   PubMedpubmed.ncbi.nlm.nih

5. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Assessing response to treatment of bone metastases from breast cancer: What should be the standard of care? 2015. Annals of Oncology. 26(6):1048–1057.
   Especially useful for: limitations of CT and bone scans for monitoring treatment response in bone metastases, and the importance of context and reproducible serial assessment.
   PubMedpubmed.ncbi.nlm.nih

6. Pope WB. Brain metastases: neuroimaging. 2018. Handbook of Clinical Neurology. 149:89–112.
   Especially useful for: why MRI is central to evaluating brain metastases, standard and advanced MRI approaches, and imaging challenges in treatment-response assessment.
   PubMedpubmed.ncbi.nlm.nih

7. Heindel W, Gübitz R, Vieth V, Weckesser M, Schober O, Schäfers M. The diagnostic imaging of bone metastases. 2014. Deutsches Ärzteblatt International. 111(44):741–747.
   Especially useful for: a clear comparison of bone scan, CT, whole-body MRI, and PET/CT, including why modalities are often used together because they measure different features of bone metastases.
   PubMedpubmed.ncbi.nlm.nih

Related

Bone Mets Hub